SCHEMBL4438324

SCHEMBL4438324

Cc1c(-c2cccc(S(=O)(=O)C[C@H](C)O)c2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 17/20 0.78
PIK3CA P42336 18/20 0.64
PIK3CB P42338 12/20 0.54
PIK3CD O00329 11/20 0.54
PIK3CG P48736 11/20 0.54
SYK P43405 2/20 0.54
MAP3K9 P80192 2/20 0.54
PIK3C2A O00443 1/20 0.54
PIK3C2B O00750 1/20 0.54
STK10 O94804 1/20 0.54
PAK4 O96013 1/20 0.54
ABL1 P00519 1/20 0.54
EGFR P00533 1/20 0.54
FGR P09769 1/20 0.54
FER P16591 1/20 0.54
PRKCA P17252 1/20 0.54
JAK1 P23458 1/20 0.54
TEC P42680 1/20 0.54
PRKDC P78527 1/20 0.54
BTK Q06187 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4556028 1.00 MTOR (0.78) MTORPIK3CAPIK3CBPIK3CDPIK3CG
SCHEMBL4435232 0.88 MTOR (1.00) MTORPIK3CAPIK3CBPIK3CDPIK3CG
SCHEMBL1860991 0.87 MTOR (0.59) MTORPIK3CAPIK3CBPIK3CDPIK3CG
SCHEMBL1860987 0.87 MTOR (0.59) MTORPIK3CAPIK3CBPIK3CDPIK3CG
SCHEMBL4445716 0.86 MTOR (0.85) MTORPIK3CAPIK3CBPIK3CDPIK3CG
SCHEMBL1859516 0.85 MTOR (0.55) MTORPIK3CAPIK3CBPIK3CDPIK3CG
SCHEMBL1859518 0.85 MTOR (0.55) MTORPIK3CAPIK3CBPIK3CDPIK3CG
SCHEMBL4447023 0.85 MTOR (0.77) MTORPIK3CAPIK3CBPIK3CDPIK3CG
SCHEMBL4439769 0.85 MTOR (0.77) MTORPIK3CAPIK3CBPIK3CDPIK3CG
SCHEMBL4554575 0.85 MTOR (0.77) MTORPIK3CAPIK3CBPIK3CDPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487533-B2 Phosphoinositide 3-kinase inhibitor compounds and methods of use GENENTECH, INC. (US) 2016-11-08 US claimed
EP-2114950-B1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2016-03-09 EP claimed
EP-2114950-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2009-11-11 EP claimed
US-20080269210-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-30 US claimed
WO-2008073785-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2008-06-19 WO claimed
US-9487533-B2 Phosphoinositide 3-kinase inhibitor compounds and methods of use GENENTECH, INC. (US) 2016-11-08 US disclosed
US-9487533-B2 Phosphoinositide 3-kinase inhibitor compounds and methods of use GENENTECH, INC. (US) 2016-11-08 US disclosed
US-9487533-B2 Phosphoinositide 3-kinase inhibitor compounds and methods of use GENENTECH, INC. (US) 2016-11-08 US disclosed
EP-2114950-B1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2016-03-09 EP disclosed
EP-2114950-B1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2016-03-09 EP disclosed
EP-2114950-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2009-11-11 EP disclosed
US-20080269210-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-30 US disclosed
US-20080269210-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-30 US disclosed
US-20080269210-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-30 US disclosed
WO-2008073785-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2008-06-19 WO disclosed
WO-2008073785-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269210-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, AKT3, PI4KA MTOR 11/4885PIK3CA 1/4885PIK3CB 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.